Literature DB >> 19906952

Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension.

Sarah F Knight1, Jianghe Yuan, Siddhartha Roy, John D Imig.   

Abstract

Obesity and hypertension are risk factors for the development of chronic kidney disease. The mechanisms by which elevated blood pressure and fatty acids lead to the development of renal injury are incompletely understood. Here, we investigated the contributions of cholesterol and oxidative stress to renal endothelial dysfunction and glomerular injury in a model of obesity and hypertension. Male Wistar-Kyoto (WKY) rats and spontaneously hypertensive rats (SHR) were fed a normal diet, a high-fat diet, a high-fat diet with tempol, or a high-fat diet with simvastatin for up to 10 wk. Blood pressure was not altered by a high-fat diet or treatments. After 3 wk, renal afferent dilatory responses to acetylcholine were impaired in WKY rats and SHR fed a high-fat diet. Tempol treatment prevented this vascular dysfunction in both strains; however, simvastatin treatment demonstrated greater beneficial effects in the SHR. Albuminuria was observed in the SHR and was exacerbated by a high-fat diet. Tempol and simvastatin treatment significantly ameliorated albuminuria in the SHR fed a high-fat diet. Ten weeks on a high-fat resulted in an increase in urinary 8-isoprostane in WKY rats and SHR, and tempol and simvastatin treatment prevented this increase, indicating a reduction in renal oxidative stress. Monocyte chemoattractant protein-1 (MCP-1) excretion was significantly elevated by a high-fat diet in both strains, and tempol prevented this increase. Interestingly, simvastatin treatment had no effect on MCP-1 levels. These data indicate that tempol and simvastatin treatment via a reduction in oxidative stress improve renal endothelial function and decrease glomerular injury in a model of obesity and hypertension.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19906952      PMCID: PMC3774183          DOI: 10.1152/ajprenal.00351.2009

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  48 in total

1.  In a type 2 diabetic nephropathy rat model, the improvement of obesity by a low calorie diet reduces oxidative/carbonyl stress and prevents diabetic nephropathy.

Authors:  Masaomi Nangaku; Yuko Izuhara; Nobuteru Usuda; Reiko Inagi; Takeo Shibata; Satoshi Sugiyama; Kiyoshi Kurokawa; Charles van Ypersele de Strihou; Toshio Miyata
Journal:  Nephrol Dial Transplant       Date:  2005-09-27       Impact factor: 5.992

2.  2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice.

Authors:  Kunihiro Ichinose; Yohei Maeshima; Yoshihiko Yamamoto; Masaru Kinomura; Kumiko Hirokoshi; Hiroyuki Kitayama; Yuki Takazawa; Hitoshi Sugiyama; Yasushi Yamasaki; Naoki Agata; Hirofumi Makino
Journal:  Diabetes       Date:  2006-05       Impact factor: 9.461

Review 3.  The role of obesity and its bioclinical correlates in the progression of chronic kidney disease.

Authors:  Laura Chalmers; Fredrick J Kaskel; Oluwatoyin Bamgbola
Journal:  Adv Chronic Kidney Dis       Date:  2006-10       Impact factor: 3.620

4.  Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats.

Authors:  Ichiro Chinen; Michio Shimabukuro; Ken Yamakawa; Namio Higa; Toshihiro Matsuzaki; Katsuhiko Noguchi; Shinichiro Ueda; Matao Sakanashi; Nobuyuki Takasu
Journal:  Endocrinology       Date:  2006-10-05       Impact factor: 4.736

5.  The expression of monocyte chemoattractant protein-1 and C-C chemokine receptor 2 in post-kidney transplant patients and the influence of simvastatin treatment.

Authors:  Jun Wang; Hequn Zou; Qingqin Li; Yuxin Wang; Qinjun Xu
Journal:  Clin Chim Acta       Date:  2006-05-12       Impact factor: 3.786

6.  Central infusion of L-arginine or superoxide dismutase does not alter arterial pressure in SHR.

Authors:  S Kagiyama; T Tsuchihashi; I Abe; K Matsumura; M Fujishima
Journal:  Hypertens Res       Date:  2000-07       Impact factor: 3.872

7.  Pathophysiologic implications of reduced podocyte number in a rat model of progressive glomerular injury.

Authors:  Daniela Macconi; Maria Bonomelli; Ariela Benigni; Tiziana Plati; Fabio Sangalli; Lorena Longaretti; Sara Conti; Hiroshi Kawachi; Prue Hill; Giuseppe Remuzzi; Andrea Remuzzi
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

8.  Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors.

Authors:  Miki Nagase; Shigetaka Yoshida; Shigeru Shibata; Takashi Nagase; Takanari Gotoda; Katsuyuki Ando; Toshiro Fujita
Journal:  J Am Soc Nephrol       Date:  2006-11-02       Impact factor: 10.121

9.  Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice.

Authors:  F Y Chow; D J Nikolic-Paterson; F Y Ma; E Ozols; B J Rollins; G H Tesch
Journal:  Diabetologia       Date:  2006-12-12       Impact factor: 10.122

10.  Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation.

Authors:  Xueliang Du; Diane Edelstein; Silvana Obici; Ninon Higham; Ming-Hui Zou; Michael Brownlee
Journal:  J Clin Invest       Date:  2006-03-09       Impact factor: 14.808

View more
  18 in total

Review 1.  Impact of obesity as an independent risk factor for the development of renal injury: implications from rat models of obesity.

Authors:  Kasi C McPherson; Corbin A Shields; Bibek Poudel; Brianca Fizer; Alyssa Pennington; Ashley Szabo-Johnson; Willie L Thompson; Denise C Cornelius; Jan M Williams
Journal:  Am J Physiol Renal Physiol       Date:  2018-12-12

2.  Systemic DNA damage accumulation under in vivo tumor growth can be inhibited by the antioxidant Tempol.

Authors:  Alexandros G Georgakilas; Christophe E Redon; Nicholas F Ferguson; Thomas B Kryston; Palak Parekh; Jennifer S Dickey; Asako J Nakamura; James B Mitchell; William M Bonner; Olga A Martin
Journal:  Cancer Lett       Date:  2014-07-25       Impact factor: 8.679

3.  EET agonist prevents adiposity and vascular dysfunction in rats fed a high fat diet via a decrease in Bach 1 and an increase in HO-1 levels.

Authors:  Komal Sodhi; Nitin Puri; Kazuyoshi Inoue; John R Falck; Michal L Schwartzman; Nader G Abraham
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-12-24       Impact factor: 3.072

4.  Increased cerebral oxygen metabolism and ischemic stress in subjects with metabolic syndrome-associated risk factors: preliminary observations.

Authors:  Ken Uchino; Ridwan Lin; Syed F Zaidi; Hiroto Kuwabara; Donald Sashin; Nicholas Bircher; Yue-Fang Chang; Maxim D Hammer; Vivek Reddy; Tudor G Jovin; Nirav Vora; Mouhammad Jumaa; Lori Massaro; Julia Billigen; Fernando Boada; Howard Yonas; Edwin M Nemoto
Journal:  Transl Stroke Res       Date:  2010-09-01       Impact factor: 6.829

5.  The nitroxide radical TEMPOL prevents obesity, hyperlipidaemia, elevation of inflammatory cytokines, and modulates atherosclerotic plaque composition in apoE-/- mice.

Authors:  Christine H J Kim; James B Mitchell; Christina A Bursill; Anastasia L Sowers; Angela Thetford; John A Cook; David M van Reyk; Michael J Davies
Journal:  Atherosclerosis       Date:  2015-03-16       Impact factor: 5.162

6.  Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome.

Authors:  Abdul Hye Khan; John D Imig
Journal:  Am J Hypertens       Date:  2011-03-17       Impact factor: 2.689

7.  Oxidative stress and inflammation in the endothelial dysfunction of obesity: a role for nuclear factor kappa B?

Authors:  John Quilley
Journal:  J Hypertens       Date:  2010-10       Impact factor: 4.844

8.  Rosiglitazone attenuates NF-κB-mediated Nox4 upregulation in hyperglycemia-activated endothelial cells.

Authors:  Clintoria R Williams; Xianghuai Lu; Roy L Sutliff; C Michael Hart
Journal:  Am J Physiol Cell Physiol       Date:  2012-05-09       Impact factor: 4.249

Review 9.  Rodent models for metabolic syndrome research.

Authors:  Sunil K Panchal; Lindsay Brown
Journal:  J Biomed Biotechnol       Date:  2010-12-30

10.  Statin use and the presence of microalbuminuria. Results from the ERICABEL trial: a non-interventional epidemiological cohort study.

Authors:  Arjan van der Tol; Wim Van Biesen; Steven Van Laecke; Kris Bogaerts; Koen De Lombaert; Hans Warrinnier; Raymond Vanholder
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.